CH
CHEOF.US Cochlear Limited
- Market cap
- USD 6.77B
- P/E
- 67.6x
- P/B
- 5.62x
- ROE
- 8.5%
- Dividend yield
- 1.75%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is CHEOF.US undervalued?
Graham numberThe Graham number of Cochlear Limited cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cochlear Limited fundamental analysis
No fundamental analysis for Cochlear Limited yet.
Cochlear Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cochlear Limited
Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers cochlear implant systems; replacement sound processors, accessories, and other services; bone conduction systems and replacement sound processors; and recipient support tools. The company also provides Cochlear connected care solutions, such as Cochlear Nucleus SmartNav System; Cochlear Custom Sound Pro Fitting Software; Cochlear Remote Assist…
Full company profileCochlear Limited financial statements
Cochlear Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.25B | 1.36B | 1.43B | 1.32B | 1.50B | 1.65B | 1.94B | 2.24B | 2.34B | 2.33B |
| Gross Profit | 895M | 1.00B | 1.08B | 976M | 1.09B | 1.24B | 1.45B | 1.67B | 1.73B | 1.64B |
| Operating Income | 316M | 306M | 371M | -244M | 370M | 402M | 390M | 475M | 406M | 301M |
| EBITDA | 348M | 383M | 409M | -185M | 452M | 475M | 487M | 577M | 620M | 406M |
| Net Income | 224M | 246M | 277M | -238M | 327M | 289M | 301M | 357M | 389M | 147M |
| EPS | 3.89 | 4.27 | 4.79 | -4.00 | 4.97 | 4.40 | 4.56 | 5.43 | 5.93 | 2.24 |
| Balance Sheet | ||||||||||
| Total Assets | 1.14B | 1.16B | 1.38B | 2.58B | 2.44B | 2.47B | 2.57B | 2.75B | 2.83B | 2.60B |
| Total Liabilities | 593M | 546M | 653M | 1.17B | 737M | 779M | 820M | 905M | 875M | 861M |
| Shareholders' Equity | 544M | 611M | 726M | 1.40B | 1.70B | 1.69B | 1.75B | 1.84B | 1.95B | 1.74B |
| Cash & Short-term Investments | 89.5M | 61.5M | 78.6M | 930M | 610M | 629M | 556M | 514M | 276M | 187M |
| Total Debt | 219M | 148M | 182M | 705M | 264M | 254M | 202M | 244M | 236M | 212M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 260M | 258M | 296M | -158M | 271M | 377M | 362M | 389M | 238M | 367M |
| Capital Expenditure | 71.1M | 49.7M | 115M | 131M | 72.6M | 77.2M | 95.9M | 89.8M | 103M | 61.0M |
| Free Cash Flow | 189M | 208M | 181M | -288M | 199M | 299M | 267M | 299M | 135M | 306M |
| Ratios | ||||||||||
| ROE | 41.1% | 40.2% | 38.1% | -17.0% | 19.2% | 17.2% | 17.2% | 19.4% | 19.9% | 8.5% |
| ROA | 19.7% | 21.2% | 20.1% | -9.3% | 13.4% | 11.7% | 11.7% | 13.0% | 13.8% | 5.7% |
| Net Profit Margin | 17.8% | 18.0% | 19.4% | -18.0% | 21.8% | 17.5% | 15.5% | 16.0% | 16.6% | 6.3% |
| Debt to Equity | 0.40x | 0.24x | 0.25x | 0.50x | 0.16x | 0.15x | 0.12x | 0.13x | 0.12x | 0.12x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cochlear Limited dividends
- Dividend yield
- 1.75%
- Forward dividend
- 1.82 USD
- Payout ratio
- 190.9%
- Ex-dividend date
- Sep 21, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | AUD 281M | 4.28 | 190.9% |
| 2025 | AUD 278M | 4.24 | 71.5% |
| 2024 | AUD 246M | 3.74 | 68.9% |
| 2023 | AUD 197M | 3.00 | 65.7% |
| 2022 | USD 194M | 2.95 | 67.1% |
| 2021 | USD 75.6M | 1.15 | 23.2% |
| 2020 | USD 194M | 3.25 | - |
| 2019 | USD 182M | 3.15 | 65.7% |
| 2018 | USD 161M | 2.80 | 65.5% |
| 2017 | USD 144M | 2.50 | 64.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Cochlear Limited
- Insiders 0.58%
- Institutions 60.01%
- Public & others 39.42%
- Shares outstanding 65.4M
- Free float 65.1M
Cochlear Limited company profile
- Company name
- Cochlear Limited
- Ticker
- CHEOF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 5,400
- Fiscal year end
- June
- Address
- 1 University Avenue, Sydney, NSW, Australia, 2109
- Phone
- 61 2 9428 6555
- Website
- cochlear.com
About Cochlear Limited
Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers cochlear implant systems; replacement sound processors, accessories, and other services; bone conduction systems and replacement sound processors; and recipient support tools. The company also provides Cochlear connected care solutions, such as Cochlear Nucleus SmartNav System; Cochlear Custom Sound Pro Fitting Software; Cochlear Remote Assist; Cochlear Remote Check; and Cochlear Link. It offers its products and services under the Cochlear, Nucleus, Nexa, Osia, and Cochlear Baha brands. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
Cochlear Limited management
10- Mr. Diggory William Howitt BE (Hons), MBACEO, MD, President & Executive Director · born 1967
- Dr. Sarah ThomChief Financial Officer
- Mr. Jan Janssen MSc Elec EngChief Technology Officer · born 1965
- Ms. Karen O'DriscollChief Information Officer
- Ms. Kristina DevonVP of Corporate Strategy & Investor Relations
- Mr. Rob McGroryGroup General Counsel & Company Secretary
- Ms. Jennifer StewartVice President of Communications, Brand & Digital Marketing
- Mr. Dean PhizackleaSenior Vice President of Global Strategic Marketing
- Ms. Sabina SopovChief People Officer, Global People & Culture
- Mr. Greg Bodkin BE (Hons), MComm (UNSW)Senior Vice President of Global Supply Chain